

Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type *TP53* Solid Tumors and Acute Leukemia



Eytan M. Stein¹, Daniel J. DeAngelo², Jörg Chromik³, Manik Chatterjee⁴, Sebastian Bauer^{5,6}, Chia-Chi Lin⁷, Cristina Suarez⁸, Filip de Vos⁹, Neeltje Steeghs¹⁰, Philippe A. Cassier¹¹, David Tai¹², Jean-Jacques Kiladjian¹³, Noboru Yamamoto¹⁴, Rogier Mous¹⁵, Jordi Esteve¹⁶, Hironobu Minami¹⁷, Stephane Ferretti¹⁸, Nelson Guerreiro¹⁸, Christophe Meille¹⁸, Rajkumar Radhakrishnan¹⁹, Bernard Pereira²⁰, Luisa Mariconti¹⁸, Ensar Halilovic²⁰, Claire Fabre¹⁸, and Cecilia Carpio²¹

ABSTRACT

Purpose: This phase I, dose-escalation study investigated the recommended dose for expansion (RDE) of siremadlin, a p53–MDM2 inhibitor, in patients with wild-type *TP53* advanced solid or hematologic cancers.

Patients and Methods: Initial dosing regimens were: 1A (day 1; 21-day cycle; dose 12.5–350 mg) and 2A (days 1–14; 28-day cycle; dose 1–20 mg). Alternative regimens included 1B (days 1 and 8; 28-day cycle) and 2C (days 1–7; 28-day cycle). The primary endpoint was incidence of dose-limiting toxicities (DLT) during cycle 1.

Results: Overall, 115 patients with solid tumors and 93 with hematologic malignancies received treatment. DLTs occurred in 8/92 patients with solid tumors and 10/53 patients with hematologic malignancies. In solid tumors, an RDE of 120 mg was defined in 1B. In hematologic tumors, RDEs were defined in 1A: 250 mg, 1B:

120 mg, and 2C: 45 mg. More patients with hematologic malignancies compared with solid tumors experienced grade 3/4 treatment-related adverse events (71% vs. 45%), most commonly resulting from myelosuppression. These were more frequent and severe in patients with hematologic malignancies; 22 patients exhibited tumor lysis syndrome. Overall response rates at the RDEs were 10.3% [95% confidence interval (CI), 2.2–27.4] in solid tumors and 4.2% (95% CI, 0.1–21.1), 20% (95% CI, 4.3–48.1), and 22.2% (95% CI, 8.6–42.3) in acute myeloid leukemia (AML) in 1B, 1A, and 2C, respectively.

Conclusions: A common safety profile was identified and preliminary activity was noted, particularly in AML. Comprehensive investigation of dosing regimens yielded recommended doses/regimens for future combination studies.

Introduction

Activation of the tumor suppressor protein p53 induces cell-cycle arrest, promotion of DNA repair pathways, and apoptosis (1–3). Murine double minute-2 (MDM2) is the primary negative regulator of p53 (4, 5). Inhibition of p53 by MDM2 is achieved through binding to the transactivation domain of p53 (6) or by acting as an E3 ubiquitin ligase of p53, resulting in proteasomal degradation (4, 7). *MDM2* is

transcriptionally upregulated by p53 activation, thus ensuring, via a negative feedback loop, low p53 activation under normal conditions (8). p53 function is often compromised in tumor cells (1, 9), by either *TP53*-inactivating mutations, amplification, and/or overexpression of *MDM2* (10).

Inhibiting MDM2 to increase wild-type p53 activity is a potentially effective antitumor approach due to the tumor suppressive effect of p53 (11, 12). Several small molecules have been developed with the

¹Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. ²Division of Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. ³Department of Medical Oncology, Goethe University Frankfurt, Frankfurt am Main, Germany. ⁴University Hospital of Würzburg, Comprehensive Cancer Center Mainfranken, Translational Oncology, Würzburg, Germany. ⁵Department of Medical Oncology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. ⁶German Consortium of Translational Cancer Research (DKTK), Essen, Germany. ⁷National Taiwan University Hospital, Taipei, Taiwan. ⁸Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. ⁹Department of Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands. ¹⁰Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. ¹¹Léon Bérard Center, Lyon, France. ¹²National Cancer Center Singapore, Singapore. ¹³Université de Paris, Hôpital Saint-Louis, Paris, France. ¹⁴National Cancer Center Hospital, Tokyo, Japan. ¹⁵Department of Hematology, University Medical Center Utrecht, Utrecht, the Netherlands. ¹⁶Hospital Clinic, IDIBAPS, Barcelona, Spain. ¹⁷Kobe University Graduate School of Medicine and Hospital, Japan. ¹⁸Novartis Institutes for BioMedical Research, Basel, Switzerland. ¹⁹Novartis Healthcare Private Limited, Hyderabad, India. ²⁰Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.

²¹Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain.

Note: Supplementary data for this article are available at Clinical Cancer Research Online (<http://clincancerres.aacrjournals.org/>).

Current address for N. Guerreiro: F. Hoffmann-La Roche, Basel, Switzerland.

Prior presentation: Data were presented in part (now updated) at the American Association for Cancer Research Annual Meeting, Washington, DC, April 1–5, 2017 and at the Japan Taiwan Oncology Phase I Trial Conference (JTOPIC), Taipei, Taiwan, April 29–30, 2017.

Corresponding Author: Eytan M. Stein, Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, David H. Koch Center for Cancer Care, 530 East 74th Street, New York, NY 10021. Phone: 646-608-3749; Fax: 212-772-8550; E-mail: SteinE@mskcc.org

Clin Cancer Res 2022;28:870–81

doi: 10.1158/1078-0432.CCR-21-1295

This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 International (CC BY-NC-ND).

©2021 The Authors; Published by the American Association for Cancer Research

Translational Relevance

Increasing the tumor suppressive activity of the p53 protein through inhibition of the p53–MDM2 interaction represents a potential therapeutic target that could offer patients with cancer new treatment options. Siremadlin, an orally bioavailable, selective inhibitor of the p53–MDM2 interaction, has demonstrated single-agent activity in preclinical studies. In this first-in-human, phase I study, patients with a range of advanced malignancies were treated with escalating doses of siremadlin. Overall, the safety profile of siremadlin did not differ significantly between tumor types and regimens. Thrombocytopenia, believed to be an on-target effect of MDM2 inhibition, was common in line with previous studies of MDM2 inhibitors. Activity was limited in patients with solid tumors, but encouraging in patients with AML. This comprehensive investigation of dosing regimens together with pharmacokinetic/pharmacodynamic modeling of thrombocytopenia yielded recommended single-agent doses and regimens for future combination studies, of which a number are ongoing in an attempt to broaden the efficacy of siremadlin.

ability to inhibit the MDM2–p53 interaction and some are currently under investigation in clinical trials, including idasanutlin, AMG-232, APG-115, BI-907828, and milademetan (13). Data from early-phase trials have demonstrated activity in various hematologic and solid cancers (14–16); however, in some cases, adverse events (AE) have limited the doses that could be administered, with the most common toxicities being gastrointestinal and bone marrow toxicities (15, 17).

Siremadlin, an orally bioavailable, selective inhibitor of the p53–MDM2 interaction, has demonstrated single-agent activity in p53 wild-type cell lines and patient-derived xenograft models (18–20). In preclinical models, fractionated low-dose siremadlin induced p21 expression and delayed accumulation of apoptotic cells, while pulsed high-dose siremadlin induced the pro-apoptotic protein PUMA and promoted rapid apoptosis (21). This first-in-human phase I dose-escalation/-expansion study aimed to determine the recommended dose for expansion (RDE). Secondary endpoints included safety and tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) properties, and preliminary antitumor activity of siremadlin in patients with wild-type *TP53* advanced solid and hematologic malignancies.

Patients and Methods

Patients

Patients were aged ≥ 18 years with Eastern Cooperative Oncology Group (ECOG) performance status 0–2 and wild-type *TP53* tumor status. Those with solid tumors had treatment-refractory locally advanced or metastatic tumors, or tumors for which no therapy was available. Those with hematologic malignancies had relapsed/refractory acute myeloid leukemia (AML) except for acute promyelocytic leukemia, or previously untreated AML unsuitable for standard induction therapy; relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) or T-cell ALL (including Philadelphia chromosome-positive ALL); or previously untreated ALL unsuitable for standard induction therapy. Patient exclusion criteria are described in the Supplementary Material.

The study adhered to International Council for Harmonisation tripartite guidelines for Good Clinical Practice, the ethical principles of the Declaration of Helsinki, and all applicable local regulations. The

study protocol was approved by all Institutional Review Boards, Independent Ethics Committees, and Research Ethics Boards. All patients provided written informed consent.

Study design

This was a first-in-human, phase I, multicenter, open-label, dose-escalation study (NCT02143635). The dose-escalation part determined the RDE of siremadlin. Dose expansion further characterized the antitumor activity of siremadlin in selected regimens.

Six regimens with different dosing schedules and cycle lengths were preplanned. Regimens high-dose 1A (dosing day 1 of a 21-day cycle; starting dose 12.5 mg) and low-dose 2A (dosing days 1–14 of 28-day cycle; starting dose 1 mg) were initially explored. Starting doses and schedules were based on preclinical data suggesting a different mechanism of action between pulsed high-dose and fractionated low-dose regimens (21). If emerging PK or safety data indicated that either regimen was suboptimal, alternative pulsed high-dose (1B: dosing days 1 and 8 of 28-day cycle; 1C: dosing day 1 of 28-day cycle) or fractionated low-dose (2B: dosing days 1–7 of 21-day cycle; 2C: dosing days 1–7 of 28-day cycle) regimens were subsequently explored (Supplementary Fig. S1). Dose escalation of siremadlin in combination with eltrombopag was also explored in a subgroup of patients with solid tumors to determine if eltrombopag could mitigate thrombocytopenia, a known class effect of MDM2 inhibitors. Three eltrombopag-containing regimens were preplanned (Supplementary Fig. S2). Treatment-related toxicities, including myelosuppression, were managed by study treatment interruption, dose reduction, and by appropriate concomitant therapies. These were mainly antifungals, growth factors, antibiotic treatments, and transfusions (for anemia and thrombocytopenia in particular).

The primary objective was to determine the RDE of siremadlin with or without eltrombopag in one or more regimens based on incidence of dose-limiting toxicities (DLT) during cycle 1. The DLT definition differed according to disease type (see Supplementary Table S1). A Bayesian logistic regression model (BLRM; ref. 22) with escalation with overdose control (EWOC) was used to guide dose escalation until the RDE was determined in one or more regimens. At least 6 patients were treated at each dose level. A two-parameter BLRM was fitted on the DLT data (i.e., absence or presence of a DLT) accumulated throughout dose escalation during the first cycle to model the dose–toxicity relationship of siremadlin.

Once the RDE was identified, additional patients were enrolled at the selected dose and regimen of siremadlin into expansion groups. These included approximately 10 patients with *TP53* wild-type liposarcoma (LPS), ~ 10 patients with other *TP53* wild-type solid tumors, and ~ 20 patients with *TP53* wild-type AML.

Analysis sets and assessments are described in the Supplementary Material.

PK and PK/PD platelet modeling

PK and PK/PD platelet models were established in a two-step approach, where individual PK estimates derived from a previously described population PK model (23) were set as a “regressor”, using the interoccasional PK estimates for the subsequent PK/PD modeling of platelets. For details on the modeling methodology and equations, please refer to the Supplementary Material.

Results

Study population

At the data cutoff (October 9, 2018), 115 patients with solid tumors and 93 patients with hematologic tumors had received treatment

(AML: $n = 91$; ALL: $n = 2$). Treatment was discontinued in 203 (98%) patients and 5 (2%) patients continue to receive treatment (all with solid tumors). The main reason for treatment discontinuation was disease progression ($n = 143$; 69%), followed by physician/patient decision ($n = 19$; 9%), AEs ($n = 18$; 9%), death ($n = 17$; 8%), withdrawal of consent ($n = 5$; 2%), and protocol deviation ($n = 1$; 0.4%).

Baseline characteristics of patients with solid tumors and hematologic malignancies are described in **Table 1**.

Dose escalation and RDE determination

Patients with solid tumors received siremadlin in high-dose 1A (every 3 weeks) at 12.5 mg, 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, 350 mg, or at 250 mg + eltrombopag; in low-dose 2A (daily; 2 weeks on/2 weeks off) at 1 mg, 2 mg, 4 mg, 7.5 mg, 15 mg, or 20 mg; in high-dose 1B (once weekly for the first 2 weeks of a 4-week cycle) at 120 mg, 150 mg, 200 mg, or at 150 mg + eltrombopag; and in low-dose 2C (daily; 1 week on/3 weeks off) at 15 mg, 20 mg, or 25 mg (Supplementary Material). No RDEs were determined for high-dose 1A, low-dose 2A, or low-dose 2C; the RDE for high-dose 1B was identified as 120 mg. RDEs were determined by the investigators and sponsor based on the probability of DLTs, and all available safety, efficacy, PK, and PD data. The median duration of exposure for all patients with solid tumors was 9.0 weeks (range, 2–193 weeks). This was quite comparable in all regimens [high-dose 1A: 8.7 weeks (range, 4–128 weeks); high-dose 1B at RDE: 12.1 weeks (range, 5–117 weeks); high-dose 1B at other doses: 10.0 weeks (range, 6–115 weeks); low-dose 2A: 8.1 weeks (range, 2–193 weeks); low-dose 2C: 8.9 weeks (range, 5–89 weeks); high-dose 1B + eltrombopag: 8.0 weeks (range, 2–110 weeks)] except for high-dose 1A + eltrombopag where the median duration of exposure was 4.1 weeks (range, 3–11 weeks). DLTs were assessed in the dose-determining set (Supplementary Material); these were all treatment related and occurred in 8/92 (9%) evaluable patients. DLT occurrence within each dosing cohort is displayed in **Table 2**. Dose escalation of siremadlin in combination with prophylactic eltrombopag was introduced for patients with solid tumors to mitigate dose-limiting thrombocytopenic events. However, a benefit of eltrombopag was not apparent and due to a limited number of patients treated ($n = 10$), the overall interpretation of the results was inconclusive. For high-dose 1A, 1/6 patients treated with 250 mg siremadlin exhibited grade 3/4 thrombocytopenia compared with 1/3 patients treated at this dose and schedule in combination with eltrombopag. In high-dose 1B, 2/8 patients treated with 150 mg siremadlin exhibited grade 3/4 thrombocytopenia compared with 1/7 treated at this dose and schedule in combination with eltrombopag. Therefore, its use was not pursued in either the expansion phase or in patients with hematologic malignancies.

Patients with hematologic malignancies received siremadlin in high-dose 1A at 250 mg, 350 mg, or 400 mg; in low-dose 2A at 20 mg, or 30 mg; in high-dose 1B at 120 mg or 150 mg; and in low-dose 2C at 45 mg (Supplementary Material). No RDE was determined for low-dose 2A; the RDEs for high-dose 1A, high-dose 1B, and low-dose 2C were 250 mg, 120 mg, and 45 mg, respectively. The median duration of exposure for all patients with hematologic tumors was 7.6 weeks (range, 1–36 weeks). This was quite comparable across all regimens [high-dose 1A at RDE: 6.1 weeks (range, 2–23 weeks); high-dose 1A at other doses: 5.4 weeks (range, 1–36 weeks); high-dose 1B at RDE: 7.5 weeks (range, 2–35 weeks); high-dose 1B at other doses: 7.9 weeks (range, 1–23 weeks); low-dose 2A: 7.6 weeks (range, 1–22 weeks); low-dose 2C at RDE: 8.3 weeks (range, 3–27 weeks)]. Grade 3/4 DLTs were all treatment related and occurred in 10/53 (19%) evaluable patients. DLT occurrence within each dosing cohort is displayed in **Table 2**.

Safety

A total of 114 (99%) patients with solid tumors and 92 (99%) patients with hematologic tumors had at least one AE regardless of cause (Supplementary Tables S2 and S3). Overall, 103 (90%) patients with solid tumors and 82 (88%) patients with hematologic malignancies had an AE suspected to be treatment related (**Table 3**). The most common of these were gastrointestinal disorders [nausea (57% solid; 44% heme), vomiting (30% solid; 18% heme), and decreased appetite (24% solid; 17% heme)], hematologic toxicities [anemia (37% solid; 42% heme), neutropenia (24% solid; 28% heme), and thrombocytopenia (33% solid; 43% heme)], and fatigue (30% solid; 13% heme). Tumor lysis syndrome was also reported in 24% of patients with hematologic malignancies, but not in patients with solid tumors. A protocol amendment was introduced during the study requiring risk assessment and safety monitoring for the potential development of tumor lysis syndrome in all patients with hematologic indications (further details are available in the Supplementary Material). For the majority of patients who experienced tumor lysis syndrome (18/22), these events occurred within the first 5 days of treatment. The median duration of tumor lysis syndrome events was 4 days (range, 2–16 days). One patient (in low-dose 2C) experienced grade 4 tumor lysis syndrome; this resolved within 4 days following dose delay and treatment with rasburicase.

Grade 3/4 AEs suspected to be treatment related were observed in 52 (45%) patients with solid tumors and 66 (71%) patients with hematologic tumors (**Table 3**). Hematologic toxicities were the most common grade 3/4 AE for all indications and were more frequent in patients with hematologic tumors compared with those with solid tumors.

A total of 50 (43.5%) patients with solid tumors and 38 (40.9%) patients with hematologic tumors had at least one AE leading to dose adjustment or interruption.

Forty-five patients (39%) with solid tumors had a grade 3/4 serious AE (SAE); in 17 (15%) of these patients, it was suspected of being treatment related. Seventy-two patients (77%) with hematologic tumors had a grade 3/4 SAE; in 42 (45%) of these patients, it was suspected of being treatment related. Six (5%) patients with solid tumors and 2 (2%) patients with hematologic tumors had a grade 3/4 AE suspected of being treatment related that led to treatment discontinuation.

There were 13 (11%) deaths among patients with solid tumors and 34 (37%) deaths among patients with hematologic malignancies during the study treatment and evaluation periods (safety follow-up continued until 30 days after the end-of-treatment visit). In patients with solid tumors, 10 deaths were considered related to underlying disease. Three deaths were considered unrelated to underlying disease: hepatic hemorrhage, hepatic failure, and pneumonia (one patient each). In patients with hematologic malignancies, 22 deaths were considered related to underlying disease. Twelve deaths were considered unrelated to underlying disease: cerebral hemorrhage, sepsis (2 patients each), euthanasia, neutropenic infection, cardiac failure, subarachnoid hemorrhage, acute kidney injury, septic shock, fungal infection, and unknown cause (1 patient each). Of the deaths from AEs in patients with hematologic malignancies, five (neutropenic infection, subarachnoid hemorrhage, acute kidney injury, and both cases of sepsis) were considered related to study treatment.

PK/PD analysis and biomarkers

PK parameters from noncompartmental analysis were summarized by dose regimen irrespective of tumor type. Following oral administration of siremadlin on day 1 of cycle 1, the median time to reach

Table 1. Baseline characteristics of patients with solid tumors or hematologic malignancies (full analysis set).

	Patients with solid tumors						Patients with hematologic malignancies						
	High-dose 1A		Low-dose 2A		Low-dose 2C		High-dose 1B		Low-dose 2A		Low-dose 2C		
	RDE (12.5-350 mg) N = 26	(19-78)	RDE (150-200 mg) N = 11	(31-75)	RDE (1-20 mg) N = 20	(58-76)	RDE (250 mg) N = 15	(30-82)	RDE (120 mg) N = 24	(28-83)	RDE (350-400 mg) N = 13	(23-81)	RDE (45 mg) N = 28
n (%) ^a	61.5 (18-80)	60.0 (19-78)	63.0 (31-75)	59.5 (38-76)	57.0 (37-74)	59.0 (18-80)	70.0 (30-82)	71.0 (23-81)	70.0 (28-83)	70.5 (64-83)	63.0 (26-72)	71.5 (28-85)	70.0 (23-85)
Sex													
Male	9 (35)	16 (55)	6 (55)	15 (75)	13 (68)	64 (56)	7 (47)	9 (69)	17 (71)	1 (17)	7 (100)	17 (61)	58 (62)
Female	17 (65)	13 (45)	5 (45)	5 (25)	6 (32)	51 (44)	8 (53)	4 (31)	7 (29)	5 (83)	0	11 (39)	35 (38)
ECOG performance status													
0	12 (46)	12 (41)	4 (36)	11 (55)	11 (58)	54 (47)	0	2 (15)	3 (13)	0	0	3 (11)	8 (9)
1	14 (54)	16 (55)	7 (64)	9 (45)	8 (42)	60 (52)	13 (87)	10 (77)	16 (67)	5 (83)	4 (57)	23 (82)	71 (76)
2	0	1 (3)	0	0	0	1 (1)	2 (13)	1 (8)	4 (17)	1 (17)	2 (29)	2 (7)	12 (13)
3	0	0	0	0	0	0	0	0	1 (4)	0	1 (14)	0	2 (2)
Prior antineoplastic regimens													
No	0	4 (14)	2 (18)	1 (5)	1 (5)	9 (8)	0	0	0	0	0	0	0
Yes	26 (100)	25 (86)	9 (82)	19 (95)	18 (95)	106 (92)	15 (100)	13 (100)	24 (100)	6 (100)	7 (100)	28 (100)	93 (100)
Number of antineoplastic regimens													
0	0	4 (14)	2 (18)	1 (5)	1 (5)	9 (8)	0	0	0	0	0	0	0
1	7 (27)	10 (34)	3 (27)	1 (5)	1 (5)	23 (20)	6 (40)	5 (38)	8 (33)	0	0	9 (32)	28 (30)
2	7 (27)	4 (14)	3 (27)	7 (35)	5 (26)	28 (24)	4 (27)	1 (8)	6 (25)	2 (33)	1 (14)	7 (25)	21 (23)
3	1 (4)	5 (17)	0	6 (30)	6 (32)	21 (18)	2 (13)	4 (31)	4 (17)	4 (31)	2 (29)	3 (11)	17 (18)
4	3 (12)	2 (7)	2 (18)	2 (10)	2 (11)	12 (10)	2 (13)	1 (8)	5 (21)	1 (17)	2 (29)	1 (4)	12 (13)
≥5	8 (31)	4 (14)	1 (9)	3 (15)	4 (21)	22 (19)	1 (7)	2 (15)	1 (4)	1 (17)	2 (29)	8 (29)	15 (16)
Primary site tumor													
Others ^c	13 (50)	4 (14)	5 (45)	5 (25)	8 (42)	39 (34)	15 (100)	12 (92)	24 (100)	6 (100)	7 (100)	27 (96)	91 (98)
Sarcoma: others ^d	8 (31)	7 (24)	0	9 (30)	5 (26)	28 (24)	0	1 (8)	0	0	0	1 (4)	2 (2)
Liposarcoma	3 (12)	12 (41)	2 (18)	1 (5)	1 (5)	19 (17)							
Uveal melanoma	2 (8)	2 (7)	2 (18)	1 (5)	1 (5)	10 (9)							
Colon	0	1 (3)	0	4 (20)	3 (16)	9 (8)							
Skin melanoma	0	3 (10)	2 (18)	2 (10)	0	8 (7)							
Kidney	0	0	0	1 (5)	1 (5)	2 (2)							
AML													
ALL													
Median time (range) since diagnosis of primary site tumor ^e , months	65.9 (6-229)	32.7 (4-301)	53.2 (10-75)	39.8 (10-116)	42.6 (2-214)	42.9 (2-301)	0	0	0	0	0	0	0
Time since diagnosis ^{f,g} , months													
<1							0	0	1/24 (4)	0	0	0	1 (1)
1-3							3/15 (20)	1/12 (8)	2/24 (8)	0	0	2/27 (7)	8/91 (9)
3-6							2/15 (13)	2/12 (17)	4/24 (17)	2/6 (33)	0	3/27 (11)	13/91 (14)
6-12							3/15 (20)	6/12 (50)	2/24 (8)	1/6 (17)	2/7 (29)	6/27 (22)	20/91 (22)
12-24							6/15 (40)	3/12 (25)	8/24 (33)	3/6 (50)	4/7 (57)	5/27 (19)	29/91 (32)
>24							1/15 (7)	0	7/24 (29)	0	1/7 (14)	11/27 (41)	20/91 (22)

(Continued on the following page)

Table 1. Baseline characteristics of patients with solid tumors or hematologic malignancies (full analysis set). (Cont'd)

n (%) ^a	Patients with solid tumors				Patients with hematologic malignancies				All patients	
	High-dose 1A (12.5–350 mg) N = 26	High-dose 1B Other doses (150–200 mg) N = 11	Low-dose 2A (1–20 mg) N = 20	Low-dose 2C (15–25 mg) N = 19	RDE (120 mg) N = 29	High-dose 1A Other doses (350–400 mg) N = 13	RDE (120 mg) N = 24	High-dose 1B Other doses (150 mg) N = 6		Low-dose 2A (20–30 mg) N = 7
Median time (range) since most recent relapse or recurrence, ^b months	2.0 (0–14)	1.6 (0–12)	1.9 (0–8)	1.9 (0–19)	1.7 (0–19)	12 (80)	10 (77)	5 (83)	6 (86)	23 (84)
Prior stem cell transplantation						3 (20)	3 (23)	2 (8)	1 (14)	5 (18)
No										
Yes										

Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ECOG, Eastern Cooperative Oncology Group; GI, gastrointestinal; GU, genitourinary; LPS, liposarcoma; RDE, recommended dose for expansion; WHO, World Health Organization.

^aUnless specified otherwise.

^bIncludes patients (*n* = 10) in cohorts receiving eltrombopag.

^cOthers include solid tumors that are not represented in the other categories of the table (including GU, GI, breast, and head and neck cancers).

^dSarcoma: others include all non-LPS soft-tissue sarcomas and bone sarcoma.

^eTo start of treatment.

^fTo start of treatment.

^gAmong patients with AML only.

maximum plasma sirmadlin concentrations (T_{max}) generally ranged from 2.0 to 8.0 hours, with a median terminal half-life ranging from 6.4 to 31.1 hours. In all regimens, dose–exposure relationships between maximum observed concentration (C_{max}) and area under the concentration–time curve from time 0 to the last measurable concentration (AUC_{last}) were approximately linear after single and repeated doses across the dose range (Fig. 1) with no apparent major deviations from dose proportionality. The interpatient variabilities for AUC_{last} and C_{max} were generally moderate. At the defined RDEs of 120 mg (high-dose 1B), 250 mg (high-dose 1A), and 45 mg (low-dose 2C) on cycle 1 day 1, the geometric mean values of C_{max} (ng/mL) were 1,039.5 [51.5 coefficient of variation (CV)%], 2,015.7 (69.5 CV%), and 425.3 (37.9 CV%), respectively, while geometric mean values of AUC_{last} (ng^{*}h/mL) were 18,481.7 (62.7 CV%), 41,422.3 (71.2 CV%), and 5,234.6 (40.7 CV%), respectively (Supplementary Table S4).

PD changes in transcriptional targets of p53 [such as growth/differentiation factor-15 (GDF-15)] were used to measure sirmadlin-driven p53 pathway activation, which demonstrated that adequate drug exposures could be achieved (21). Despite limited data, a clear trend was observed for increases in serum GDF-15 with higher exposure (as measured by AUC_{last}) of sirmadlin for both high-dose regimens (1A/1B) and low-dose regimens (2A/2C; Fig. 2). This exposure-dependent increase in GDF-15 was also maintained on day 2 of treatment cycle 2 (C2D2; Supplementary Fig. S3). High-dose regimens, especially for $AUC_{last} > 10,000$ ng/mL^{*}h, showed > 210-fold changes on an average in GDF-15 for both C1D2 (*P* = 0.002) and C2D2 (*P* = 0.009), respectively (Fig. 2; Supplementary Fig. S3).

To determine how baseline biomarker status may relate to clinical outcome, next-generation sequencing (NGS) was performed on pretreatment solid tumor samples. Gene alterations in 324 genes were evaluated in 48 patients using the FoundationOne panel (24). Somatic copy-number amplifications in *MDM2* were observed in 16 of 48 patients analyzed (Fig. 3A). Although statistically underpowered to robustly detect associations, *MDM2* amplification was more prevalent in patients who achieved either partial response (PR) or stable disease (SD; 9/17 patients with *MDM2* amplification; 53.0%) than in patients with progressive disease (PD; 6/26; 23.0%; Fig. 3B). For patients whose tumors had *MDM2* amplification, those with PD also had a higher total number of somatic alterations (range of total alterations: 4–10 in 6 patients) compared with those who had either PR or SD (range, 2–6 in 9 patients; Fig. 3C). In patients with PD, concomitant alterations included deletion of *CDKN2A* (2/6 tumors), deletion of *ATRX* (2/6 tumors), amplification of *KRAS* (2/6 tumors), point mutation in *AKT1* (1/6 tumors), and amplification of *CDK6* (1/6 tumors; Fig. 3A). These data suggest that the presence of *MDM2* amplification in tumors at baseline may be associated with better clinical outcomes. However, the presence of additional oncogenic alterations in *MDM2*-amplified tumors may be associated with patient progression on treatment.

Semi-mechanistic PK/PD analysis of platelet kinetics in solid tumor patients

A semi-mechanistic PK/PD model modified from Friberg and colleagues (25) was developed to investigate drug action on the time course of platelet in solid tumor patients treated with sirmadlin. This model, mimicking the hematopoietic process, was modified from Friberg and colleagues (25) to assume a drug direct action characterized by the parameter (*kr1D*) on proliferating progenitor compartment (*P1*; see Supplementary Fig. S4). For details on the PK/PD modeling methodology and equations, please refer to the Supplementary Material.

Table 2. Dose levels tested and DLTs across the regimens in solid and hematologic tumors.

Regimen	Solid tumors			Hematologic tumors		
	Siremadlin dose, mg	n	DLTs, n	Siremadlin dose, mg	n	DLTs, n
High-dose 1A^a	12.5	1	0	250 ^b	15	• 1 pt: G3 cardiac failure • 1 pt: G4 staphylococcal sepsis • 1 pt: G4 hyperuricemia
	25	1	0	350	4	0
	50	4	0	400	9	• 1 pt: G3 chronic GvHD + G3 stomatitis + G3 neutropenic infection • 1 pt: G4 subarachnoid hemorrhage • 2 pts: G4 hypophosphatemia
	100	4	0			
	200	5	0			
	250	6	0			
	350	5	• 1 pt: G4 thrombocytopenia • 1 pt: G3 neutrophil count decreased + G4 platelet count decreased			
	250 + eltrombopag ^c	3	• 1 pt: G4 leukopenia + G4 neutropenia + G4 thrombocytopenia + G3 febrile neutropenia • 1 pt: G3 anemia + G3 platelet count decreased			
High-dose 1B^d	120 ^b	29	0	120 ^b	24	0
	150	8	• 1 pt: G3 neutropenia	150	6	• 1 pt: G4 acute kidney injury + G3 hyperkalemia
	200	3	0			
	150 + eltrombopag ^e	7	• 1 pt: G3 platelet count decreased			
Low-dose 2A^f	1	1	0	20	3	• 1 pt: G3 C-reactive protein increased
	2	2	0	30	4	0
	4	4	0			
	7.5	4	0			
	15	4	0			
	20	5	0			
Low-dose 2C^g	15	8	0	45 ^b	28	• 1 pt: G4 tumor lysis syndrome
	20	6	0			
	25	5	• 1 pt: G4 lipase increased + G4 amylase increased • 1 pt: G3 platelet count decreased			

Abbreviations: DLT, dose-limiting toxicity; G, grade; GvHD, graft-versus-host disease; pt, patient; RDE, recommended dose for expansion.

^aHigh-dose 1A: on day 1 of a 21-day cycle.

^bRDE.

^cOnce daily for 10 consecutive days, starting on day 12 of siremadlin cycle 1 and from cycle 2 onward on the second day after last siremadlin administration.

^dHigh-dose 1B: on days 1 and 8 of a 28-day cycle.

^eOnce daily for 10 consecutive days starting on day 19 of siremadlin cycle 1 and from cycle 2 onward on the second day after last siremadlin administration.

^fLow-dose 2A: on days 1–14 of a 28-day cycle.

^gLow-dose 2C: on days 1–7 of a 28-day cycle.

In brief, the PK/PD model was able to adequately describe the long-term platelet profiles up to 25 months. Parameter estimates from the final PK/PD model are reported in Supplementary Table S5. In general, all parameters were well estimated with good precision as indicated from relative standard errors, most of them below 50%. A low residual error (additive 12 G/L and proportional 13.6%) was estimated indicating good model description of the data.

The drug effect on early proliferative hematopoietic cells was associated with an estimated mean maturation time (*MMTP*) of 294 hours, reflecting the delayed onset of siremadlin-induced thrombocytopenia and the long platelet recovery time observed in patients. Additionally, assuming an indirect drug effect reducing with time the regulation capacity of the proliferative compartment helped describe the progressive depletion of platelets observed with increasing treatment cycles. Variability on this part of the model was high (IIV of *ke01* 119% and *ke0* 84%), reflecting

the broad range of sensitivity across patients in response to bone marrow toxicity.

Individual platelet profile fitting (Supplementary Fig. S5) illustrates model flexibility to capture a diverse array of profiles. Goodness-of-fit diagnostic plots did not show any obvious bias (Supplementary Fig. S6). The predictive performance of the final model was checked by Monte Carlo simulations of the population model and plotting a visual predictive check (Supplementary Fig. S7). Most of the 10th, 50th, and 90th percentiles of the observed platelet data were included in the respective model 90% prediction intervals indicating adequate description by the model. The thrombocytopenia model, together with previously described modeling of tumor growth inhibition by siremadlin (18), provided a consolidated approach to support the selection of dosing regimen(s) for following clinical trials, which allows maximization of the total dose per cycle for efficacy while mitigating the occurrence of severe thrombocytopenia (26).

Table 3. AEs suspected to be related to treatment (occurring in >5% of all patients with solid or hematologic malignancies).

n (%)	Patients with solid tumors												Patients with hematologic malignancies																																											
	High-dose 1A				Low-dose 2A				Low-dose 2C				All patients ^a				High-dose 1B				Low-dose 2A				Low-dose 2C				All patients																											
	Other doses				Other doses				Other doses				Other doses				Other doses				Other doses				Other doses				Other doses				Other doses																							
	RDE (120 mg)				RDE (150 mg)				RDE (250 mg)				RDE (350-400 mg)				RDE (120 mg)				RDE (20-30 mg)				RDE (45 mg)				RDE (150 mg)				RDE (120 mg)				RDE (20-30 mg)				RDE (45 mg)				RDE (150 mg)											
	N = 26				N = 29				N = 11				N = 20				N = 19				N = 115				N = 15				N = 13				N = 24				N = 6				N = 7				N = 28				N = 93							
	Any				3/4				Any				3/4				Any				3/4				Any				3/4				Any				3/4				Any				3/4				Any				3/4			
Number of patients with ≥ 1 AE	25 (96)	10 (39)	29 (100)	16 (55)	10 (91)	5 (46)	14 (70)	8 (40)	15 (79)	9 (47)	103 (90)	52 (45)	14 (93)	14 (93)	12 (92)	9 (69)	19 (79)	13 (54)	5 (83)	5 (83)	5 (71)	3 (43)	27 (96)	22 (79)	82 (88)	66 (71)																														
Nausea	17 (65)	0	20 (69)	2 (7)	6 (55)	0	8 (40)	0	8 (42)	0	66 (57)	2 (2)	6 (40)	0	8 (62)	0	6 (25)	0	4 (67)	0	3 (43)	0	14 (50)	0	41 (44)	0																														
Anemia	10 (39)	3 (12)	15 (52)	6 (21)	5 (46)	1 (9)	6 (30)	4 (20)	4 (21)	3 (16)	43 (37)	18 (16)	8 (53)	5 (33)	5 (39)	4 (31)	8 (33)	4 (17)	2 (33)	2 (33)	3 (43)	2 (29)	13 (46)	9 (32)	39 (42)	26 (28)																														
Thrombocytopenia	9 (35)	6 (23)	4 (14)	4 (36)	2 (18)	0	7 (35)	4 (20)	6 (32)	3 (16)	38 (33)	2 (18)	7 (47)	7 (54)	7 (54)	7 (54)	10 (42)	3 (50)	3 (50)	2 (29)	2 (29)	11 (39)	10 (36)	40 (43)	39 (42)																															
Fatigue	6 (23)	0	9 (31)	0	5 (46)	1 (9)	4 (20)	0	5 (26)	1 (5)	34 (30)	2 (2)	2 (13)	1 (7)	4 (31)	0	1 (4)	0	0	0	0	0	5 (18)	2 (7)	12 (13)	3 (3)																														
Vomiting	8 (31)	0	12 (41)	1 (3)	3 (27)	0	4 (20)	0	4 (21)	0	34 (30)	1 (1)	5 (39)	0	5 (39)	0	3 (13)	0	0	0	1 (14)	0	6 (21)	0	17 (18)	0																														
Decreased appetite	8 (31)	1 (4)	8 (28)	0	4 (36)	0	4 (20)	0	3 (16)	1 (5)	27 (24)	2 (2)	3 (20)	1 (7)	4 (31)	0	1 (4)	0	1 (17)	0	1 (14)	0	6 (21)	0	16 (17)	1 (1)																														
Neutropenia	7 (27)	6 (23)	9 (31)	8 (28)	4 (36)	3 (27)	4 (20)	3 (15)	1 (5)	27 (24)	22 (19)	6 (40)	5 (33)	5 (39)	5 (39)	5 (39)	5 (21)	5 (21)	1 (17)	1 (17)	0	0	9 (32)	8 (29)	26 (28)	24 (26)																														
Platelet count decreased	3 (12)	2 (8)	9 (31)	3 (10)	2 (18)	0	3 (15)	3 (15)	2 (11)	1 (5)	22 (19)	11 (10)	2 (13)	2 (13)	0	0	1 (4)	1 (4)	0	0	0	0	2 (7)	2 (7)	5 (5)	5 (5)																														
White blood cell count decreased	5 (19)	2 (8)	7 (24)	2 (7)	2 (18)	0	2 (10)	1 (5)	1 (5)	0	18 (16)	5 (4)	1 (7)	1 (7)	1 (8)	0	0	0	0	0	1 (14)	1 (14)	3 (11)	3 (11)	6 (7)	5 (5)																														
Diarrhea	4 (15)	0	5 (17)	0	2 (18)	0	2 (10)	0	2 (11)	0	16 (14)	0	5 (33)	0	3 (23)	0	2 (8)	0	0	0	0	0	2 (7)	0	12 (13)	0																														
Leukopenia	5 (19)	3 (12)	5 (17)	1 (3)	1 (9)	1 (9)	3 (15)	2 (10)	1 (5)	1 (5)	16 (14)	9 (8)	2 (13)	2 (13)	2 (15)	2 (15)	3 (13)	3 (13)	0	0	0	0	2 (7)	2 (7)	9 (10)	9 (10)																														
Lymphopenia	4 (15)	1 (4)	3 (10)	2 (7)	3 (27)	1 (9)	1 (5)	0	0	0	13 (11)	5 (4)	0	0	0	0	0	0	0	0	0	0	1 (4)	1 (4)	1 (1)	1 (1)																														
Dysgeusia	3 (12)	0	3 (10)	0	1 (9)	0	2 (10)	0	2 (11)	0	12 (10)	0	0	0	1 (8)	0	0	0	0	0	0	0	1 (4)	0	2 (2)	0																														
Neutrophil count decreased	2 (8)	2 (8)	2 (7)	3 (27)	1 (9)	2 (10)	1 (5)	2 (11)	1 (5)	0	8 (7)	0	0	0	0	0	0	0	0	0	1 (14)	1 (14)	2 (7)	2 (7)	3 (3)	3 (3)																														
Asthenia	3 (12)	1 (4)	3 (10)	0	1 (9)	0	2 (10)	0	1 (5)	0	10 (9)	1 (1)	2 (13)	1 (7)	1 (8)	0	4 (17)	2 (8)	1 (7)	0	0	0	2 (7)	0	10 (11)	3 (3)																														
Abdominal pain	2 (8)	1 (4)	2 (7)	0	2 (18)	0	1 (5)	0	0	0	8 (7)	1 (1)	2 (13)	0	1 (8)	0	1 (4)	0	0	0	0	0	0	0	4 (4)	0																														
Weight decreased	2 (8)	0	2 (7)	0	1 (9)	0	2 (10)	0	1 (5)	0	8 (7)	0	0	0	1 (8)	0	0	0	0	0	0	0	0	0	2 (2)	0																														
AST increased	1 (4)	0	0	0	0	0	3 (15)	1 (5)	0	2 (2)	7 (6)	2 (2)	1 (7)	0	0	0	0	0	0	0	0	0	0	0	2 (7)	2 (2)																														
Constipation	3 (12)	0	1 (3)	0	0	0	2 (10)	0	1 (5)	0	7 (6)	0	0	0	0	0	0	0	0	0	0	0	0	0	1 (4)	0																														
Lipase increased	1 (4)	0	2 (7)	0	3 (27)	3 (27)	0	0	1 (5)	1 (5)	7 (6)	4 (4)	0	0	3 (23)	2 (15)	1 (4)	1 (4)	0	0	0	0	1 (4)	1 (4)	5 (5)	4 (4)																														
Tumor lysis syndrome	0	0	0	0	0	0	0	0	0	0	0	0	8 (53)	7 (47)	5 (39)	5 (39)	5 (21)	5 (21)	0	0	1 (14)	1 (14)	3 (11)	3 (11)	22 (24)	21 (23)																														
Febrile neutropenia	1 (4)	1 (4)	1 (3)	1 (3)	0	0	0	0	0	0	3 (3)	3 (3)	4 (27)	4 (27)	3 (23)	3 (23)	1 (4)	1 (4)	2 (33)	2 (33)	2 (29)	2 (29)	9 (32)	9 (32)	21 (23)																															
Hyperuricemia	0	0	0	0	0	0	0	0	1 (5)	0	2 (2)	0	2 (13)	1 (7)	1 (8)	0	1 (4)	1 (4)	2 (33)	0	1 (14)	0	2 (7)	1 (4)	9 (10)	2 (2)																														
Hypocalcemia	0	0	2 (7)	0	1 (9)	0	0	0	0	0	3 (3)	0	3 (20)	1 (7)	2 (15)	0	1 (4)	0	0	0	0	0	3 (11)	0	9 (10)	1 (1)																														
Amylase increased	0	0	0	0	0	0	0	0	0	0	0	0	1 (7)	1 (7)	3 (23)	0	2 (8)	1 (4)	1 (17)	1 (17)	0	0	1 (4)	0	8 (9)	3 (3)																														
Acute kidney injury	1 (4)	0	0	0	0	0	0	0	0	1 (1)	0	0	0	0	1 (8)	0	1 (4)	0	1 (17)	1 (17)	1 (14)	0	2 (7)	1 (4)	6 (7)	2 (2)																														
Blood creatinine increased	1 (4)	0	1 (3)	0	0	0	1 (5)	0	1 (5)	0	4 (4)	0	2 (13)	0	1 (8)	0	0	0	0	0	1 (14)	0	2 (7)	0	6 (7)	0																														
Febrile bone marrow aplasia	0	0	0	0	0	0	0	0	0	0	0	0	2 (13)	1 (7)	0	0	4 (17)	3 (13)	0	0	0	0	0	0	6 (7)	4 (4)																														
Hyperphosphatemia	0	0	0	0	0	0	0	0	0	0	0	0	2 (13)	0	1 (8)	0	1 (4)	0	1 (17)	0	0	0	1 (4)	0	6 (7)	0																														
Hypoalbuminemia	0	0	1 (3)	0	0	0	1 (5)	0	0	0	2 (2)	0	1 (7)	1 (7)	2 (15)	2 (15)	1 (4)	0	0	0	0	0	2 (7)	1 (4)	6 (7)	4 (4)																														
Hypotension	2 (8)	1 (4)	0	0	0	0	0	0	0	2 (2)	1 (1)	0	1 (7)	0	1 (8)	0	2 (8)	0	0	0	0	0	2 (7)	1 (4)	6 (7)	1 (1)																														
Alopecia	2 (8)	0	0	0	0	0	0	0	0	4 (4)	0	0	1 (7)	0	1 (8)	0	1 (4)	0	0	0	0	0	3 (11)	0	5 (5)	0																														
Blood phosphorus increased	0	0	0	0	0	0	0	0	0	0	0	0	2 (13)	0	1 (8)	0	1 (4)	0	1 (17)	0	0	0	0	0	5 (5)	0																														
Hyperkalemia	0	0	1 (3)	0	0	0	0	0	0	0	1 (1)	0	3 (20)	1 (7)	0	0	0	0	1 (17)	1 (17)	0	0	1 (4)	1 (4)	5 (5)	3 (3)																														
Malaise	1 (4)	0	0	0	0	0	0	0	0	2 (2)	0	0	1 (7)	0	1 (8)	0	2 (8)	0	0	0	1 (14)	0	1 (4)	0	5 (5)	0																														
Pyrexia	0	0	2 (7)	0	0	0	0	0	0	3 (3)	0	1 (7)	0	3 (23)	0	0	0	0	0	0	1 (14)	0	0	0	5 (5)	0																														

Abbreviations: AE, adverse event; AST, aspartate aminotransferase; RDE, recommended dose for expansion.
^aIncludes patients (n = 10) in cohorts receiving eltrombopag.




Figure 1.

Relationship between siremadlin dose and noncompartmental PK parameters for cycle 1 day 1 in all patients (PK analysis set). **A**, High-dose 1A (dose range, 50–400 mg) $n = 57$; **B**, low-dose 2A (dose range, 1–30 mg) $n = 27$; **C**, low-dose 2C (dose range, 15–45 mg) $n = 45$. The solid lines shown in the figure are based on the fitted model: PK parameter = $\exp(\alpha) \cdot \text{dose} \cdot \beta$. AUC_{last} : high-dose 1A is represented by 0–48 hour; low-dose 2A cycle 1 day 1 and day 14 by 0–24 and 0–8 hour, respectively; low-dose 2C cycle 1 day 1 and day 7 by 0–24 and 0–8 hour, respectively. AUC_{last} , area under the concentration–time curve from time 0 to last measurable concentration; C_{max} , maximum observed concentration; PK, pharmacokinetic.

Antitumor activity

Among patients with solid tumors, the overall response rate [ORR: complete remission (CR) + PR] was 3.5% [95% confidence interval (CI), 1.0–8.7]; the disease control rate (DCR) was 36.5% (95%

CI, 27.7–46.0). Three patients in high-dose 1B and one in high-dose 1A achieved a PR (Supplementary Table S6). Responding patients had tracheal hemangiopericytoma (solitary fibrous tumor; $n = 1$), intimal sarcoma ($n = 2$), or LPS ($n = 1$). Initial responses were achieved at 27,




Figure 2.

Representation of individual GDF-15 serum levels expressed as a fold change between predose and 24 hours after dose of siremadlin (CID2) as it relates to drug serum concentration (AUC_{last}). AUC_{last} calculated on 0–48 hour for high-dose 1A/1B and 0–24 hour for low-dose 2A/2C. All patients irrespective of the cancer type are depicted. AML, acute myeloid leukemia; CID2, cycle 1, day 2; GDF-15, growth/differentiation factor-15.




Figure 3.

Genetic alterations detected by NGS in relation to the clinical outcome. **A**, Alterations in 324 cancer-associated genes were evaluated using FoundationOne sequencing in 48 patients with solid tumors. Detected pretreatment somatic alterations of known and likely significance in each patient are depicted together with clinical outcome. Heatmap colors indicate alteration type in the 20 genes most frequently altered across the gene panel. Best overall response (BOR) is also shown for each patient. The numbers and types of alterations identified in each gene are indicated by the bars on the right of the heatmap. Genes with copy number ≥ 6 were defined as amplified. **B**, *MDM2* status by clinical outcome. The frequency of somatic amplifications in *MDM2* is depicted in patients with better (PR/SD) or worse (PD) clinical outcomes. **C**, Total number of somatic alterations in patients with solid tumors in relation to *MDM2* amplification and clinical outcome. Somatic alterations include copy-number and point mutation events in any of the 324 genes in the FoundationOne panel. Total alteration counts shown here are stratified by patients with better (PR/SD) or worse (PD) clinical outcomes. Points are colored by *MDM2* amplification status. AMP, copy-number amplification; DEL, deletion; MDM2-AMP, *MDM2* with copy-number amplification; MDM2-NEUT, *MDM2* with neutral copy number; MUT, point mutation; NGS, next-generation sequencing; PD, progressive disease; PR, partial response; SD, stable disease; UNK, unknown.

71, 114, and 117 days after treatment began and lasted 79, 92, 452, and 459 days, respectively. No patient achieved CR, but 38 (33%) achieved SD (note that 16/38 patients had LPS, which often has an indolent course). Best percentage change in target lesions from baseline in patients with LPS treated at the RDE is shown in Supplementary Fig. S8. The patient with PR achieved a tumor reduction of 80.84%.

Among the 91 patients with AML, 5 achieved CR (2 patients were treated with high-dose 1A, 1 with high-dose 1B, and 2 with low-dose 2C). CR was achieved at 30, 31, 36, 41, and 50 days of treatment in all responding patients and lasted for 49, 77, and 151 days in 3 patients who eventually relapsed; one patient continues to respond after 141 days and one patient did not have another assessment following initial CR. All 5 responding patients with AML had received at least two prior lines of therapy. In the 4 responding patients with cytogenetic data available, 3 had intermediate risk cytogenetics (trisomy 8, -Y, and normal) and 1 had unfavorable cytogenetics (del7q). The ORR [CR + morphologic CR with incomplete blood count recovery (CRi) + PR] in these patients was 13.2% (95% CI, 7.0–21.9; 5 CR and 7 CRi) overall, and 4.2% (95% CI, 0.1–21.1; 1 CR), 20% (95% CI, 4.3–48.1; 1 CR and 2 CRi) and 22.2% (95% CI, 8.6–42.3; 2 CR and 4 CRi) in those treated at the identified RDEs in high-dose 1B, high-dose 1A, and low-dose 2C, respectively (Supplementary Table S8). There were also patients with a greater than 50% decrease in blast count; however, all necessary criteria for assigning a PR were not met. Two patients,

one who had achieved a CRi and one who had not responded (both treated with low-dose 2C), received an allogeneic stem cell transplant following treatment discontinuation. It should be noted that transplantations that occurred later than 30 days after the last treatment dose were not recorded.

Twelve patients with LPS were enrolled and treated with siremadlin at the RDE for high-dose 1B (120 mg) in the dose-expansion phase of the study. Of these, none achieved CR but 1 (8%) achieved a PR and 9 (75%) achieved SD; the DCR in these 12 patients was 83.3% (95% CI, 51.6–97.9). Ten of these patients had a progression-free survival (PFS) event of disease progression and 2 were censored. Median PFS for these 12 patients was 5.6 months (95% CI, 1.9–12.9). Of the 9 patients with SD, 3 patients achieved SD for >6 months.

Discussion

The p53 protein plays a critical role in tumor suppression by inducing growth arrest, apoptosis, and senescence of tumors in addition to blocking angiogenesis (27). Increasing p53 activity represents a potential therapeutic target that could offer patients with a range of different tumor types new treatment options (11, 27, 28). In this study, escalating doses of siremadlin were explored in two fractionated low-dose (2A or 2C) and two pulsed high-dose (1A and 1B) regimens for various indications based on preclinical data (21). Siremadlin displayed linear PK in the tested dose range across all

regimens, with moderate interpatient variabilities for AUC_{last} and C_{max} . Observation of dose-dependent induction of GDF-15 suggested that p53 pathway activation, and therefore biological target engagement, was achieved with siremadlin, in line with previous observations (21). For patients with solid tumors, an RDE of 120 mg was declared with high-dose 1B, while in patients with hematologic malignancies three RDEs were declared: 250 mg, 120 mg, and 45 mg with high-dose 1A, high-dose 1B, and low-dose 2C, respectively. For hematologic malignancies, these RDEs account for different siremadlin regimens: fractionated low dose and pulsed high dose that have been linked preclinically with a different mechanism of action. In addition, they offer a broader range of options for future siremadlin-based combinations.

Overall, the safety profile of siremadlin did not differ significantly between tumor types and regimens. Thrombocytopenia, believed to be an on-target effect of MDM2 inhibition (29), was common in line with previous studies of MDM2 inhibitors (17, 30). Moreover, the delayed onset of siremadlin-induced thrombocytopenia and the long platelet recovery time was likely related to the preferential effect of siremadlin on early proliferative hematopoietic cells. This effect is reflected by the PK/PD model-derived mean maturation time on circulating platelets of 294 hours, which is consistent with that of other MDM2 inhibitors (31), and supportive of short-term high-dose treatment intervals. Furthermore, preclinical and clinical model-based PK/PD analysis showed siremadlin antitumor growth activity not to be regimen-dependent. That is, equivalent antitumor activity could be achieved across regimens providing that the same average concentrations or cumulative dose were achieved per treatment cycle (18). This is of clinical importance as it allows the optimization of dosing regimens to mitigate occurrence of severe myelosuppression that would otherwise be associated with prolonged continuous administration of siremadlin. The reported thrombocytopenia model was used to simulate and guide decisions on dosing regimen(s) selection based on maximizing the total dose per cycle for efficacy while mitigating the occurrence of severe thrombocytopenia (26).

Tumor lysis syndrome was reported in 24% of patients with hematologic malignancies, providing an indication of the antileukemic activity of treatment. It will be necessary to consider the AE and prevention strategies in future development. Other common AEs included gastrointestinal toxicities of lower grade and hematologic toxicities. Compared with patients with solid tumors, more patients with hematologic malignancies had grade 3/4 AEs (71% vs. 45%) and grade 3/4 SAEs (45% vs. 15%). Disease severity at baseline and baseline bone marrow myelosuppression may have contributed to these differences in both severity and incidence of hematologic toxicities. More patients with hematologic malignancies died during study evaluation (37% vs. 11% of patients with solid tumors); however, most deaths were due to underlying disease.

In patients with solid tumors, antitumor activity was limited [ORR = 10.3% (95% CI, 2.2–27.4), comprising 3 PRs] among the 29 patients treated with the RDE, possibly due to tumor heterogeneity. For the 12 patients with *TP53* wild-type LPS enrolled in the expansion group, a DCR of 83.3% (95% CI, 51.6–97.9; comprising 1 PR and 9 SD) was achieved. It should be noted, LPS often presents with an indolent course. However, LPS may be particularly sensitive to siremadlin given the characteristic amplification and/or overexpression of *MDM2* observed in LPS tumors (32, 33). The results for patients with solid tumors highlight the need for combining siremadlin with other agents to potentially improve efficacy.

Among patients with hematologic malignancies treated at the RDEs, antitumor activity was more apparent in high-dose 1A (ORR,

20%; 95% CI, 4.3–48.1, comprising 1 CR and 2 CRis) and low-dose 2C (ORR, 22.2%; 95% CI, 8.6–42.3, comprising 2 CRs and 4 CRis) compared with high-dose 1B (ORR, 4.2%; 95% CI, 0.1–21.1, comprising 1 CR). Five patients with AML across all dosing cohorts of these three regimens achieved CR. This outcome is encouraging given that about one third of patients had received more than three lines of prior therapy and 16% had received prior stem cell transplantation; this compares favorably with other salvage therapies for AML (34, 35).

In 48 patients with solid tumors enrolled based on local assessment of *TP53*, *TP53* sequencing was reassessed centrally using NGS with the FoundationOne panel, whereby alterations were discovered in 3 patients (2 with somatic mutation and 1 with deletion in *TP53*). All 3 patients progressed immediately on treatment. There are several potential reasons for these discrepancies in *TP53* sequencing. They could be due to the sensitivity and ability of different assays to detect mutations with lower allelic frequency. Also, sequencing was done on different biopsy samples, which could have been collected from different lesions, with different *TP53* status. In addition, archival tissue collected months before the study enrollment was allowed for screening. As the incidence of *TP53* mutations may increase with therapy-related genomic instability, this may have contributed to the detection of *TP53* mutations after the patient had been enrolled in the study (36).

In this study, siremadlin demonstrated a tolerable safety profile consistent with previous observations of siremadlin and other MDM2 inhibitors. DLTs of thrombocytopenia were manageable. Efficacy was limited in patients with solid tumors, although patients with LPS in the expansion group achieved excellent disease control. The emergence of *TP53* mutations following treatment with this class of compounds has been previously reported (37); this was not evaluated in the current study, but is planned for investigation in an ongoing study of patients with AML and high-risk myelodysplastic syndromes (MDS; NCT03940352). Siremadlin is being investigated in combination with other agents in an attempt to broaden its efficacy; these include a cyclin-dependent kinase-4 inhibitor for LPS (NCT02343172), anti-programmed cell death protein-1 for colorectal cancer and renal cell carcinoma (NCT02890069), and a Janus kinase 1/2 inhibitor for myelofibrosis (NCT04097821). Combinations with an anti-TIM3 and with B-cell lymphoma-2 (Bcl2) inhibitor for AML and high-risk MDS (NCT03940352) are also being explored.

Data sharing statement

Novartis is committed to sharing with qualified external researchers, access to patient-level data, and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided are anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described at www.clinicalstudydatarequest.com.

The sequencing data described in this publication will be made available for any qualified request. To submit a request, please contact: novartis.datasharing@novartis.com.

Authors' Disclosures

E.M. Stein reports personal fees from Novartis during the conduct of the study, as well as personal fees from Astellas, Daiichi, Syndax, Agios, Celgene, and BMS outside the submitted work. J. Chromik reports personal fees from Alexion, Novartis, BMS, and Celgene outside the submitted work. S. Bauer reports personal fees from Daiichi Sankyo, as well as grants and personal fees from Novartis during the conduct of the study. S. Bauer also reports personal fees from Novartis, Deciphera, GSK, Daiichi

Sankyo, Roche, Exelixis, Bayer, and Pharmamar; grants and personal fees from Blueprint Medicines; and grants from Incyte outside the submitted work. C.-C. Lin reports personal fees from BeiGene, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Novartis, PharmaEngine, Roche, and AbbVie outside the submitted work. C. Suarez reports grants from AB Science, Aragon Pharmaceuticals and AstraZeneca AB, Blueprint Medicines Corporation, Boehringer Ingelheim España, S.A., Clovis Oncology, Exelixis Inc, F., Genentech Inc, GlaxoSmithKline, S.A. and Novartis Farmacéutica, S.A.; grants and personal fees from Astellas Pharma, Bayer, Bristol Myers Squibb (Inst), Hoffmann-La Roche LTD, Pfizer S.L.U. and Sanofi-Aventis; and personal fees from Eusa Pharma, Ipsen, Merck Sharp & Dohme Corp., and Novartis outside the submitted work. F. de Vos reports research funding to institution from AbbVie, BioClin Therapeutics, Bristol Myers Squibb, GlaxoSmithKline, Novartis, Octimet Oncology, and VAXIMM. F. de Vos received funding for expert testimony from Bristol Myers Squibb, as well as travel and accommodations from Roche/Genentech. N. Steeghs reports multiple grants to institution (Netherlands Cancer Institute) during the conduct of the study and outside the submitted work. P.A. Cassier reports other support from Novartis during the conduct of the study. P.A. Cassier also reports other support from AbbVie, Adlai Nortye, Alligator, Bayer, BMS, Boston, Exelixis, GSK, Innate Pharma, Iteos, Janssen, Lilly/Loxo, Molecular Partners, OSE, Roche/Genetech, Sotio, Taiho, Toray, Transgene, and MSD; personal fees and other support from Amgen; non-financial support from AstraZeneca; non-financial support and other support from Debio; personal fees from EMD Serono; and grants and other support from Novartis outside the submitted work. D. Tai reports grants from BMS, Sirtex, and Novartis outside the submitted work. J.-J. Kiladjian reports personal fees from Novartis during the conduct of the study, as well as personal fees from AbbVie and BMS outside the submitted work. N. Yamamoto reports grants from Astellas, Chugai, Eisai, Taiho, BMS, Pfizer, Novartis, Eli Lilly, AbbVie, Daiichi Sankyo, Bayer, Boehringer Ingelheim, Kyowa-Hakko Kirin, Takeda, ONO, Janssen Pharma, MSD, Merck, GSK, Sumitomo Dainippon, Chiome Bioscience, Otsuka, Carina Biosciences, and Genmab, as well as personal fees from Eisai, Takeda, Otsuka, Boehringer Ingelheim, Cimic, and Chugai outside the submitted work. J. Esteve reports personal fees from AbbVie, Jazz Pharmaceuticals, Novartis, Astellas, Bristol Myers Squibb–Celgene, and Novartis outside the submitted work. H. Minami reports grants from Novartis during the conduct of the study. H. Minami also reports grants from Astellas, Boehringer, Merck Serono, CSL Behring, Nihon Kayaku, Shionogi, Nihon Shinyaku, and Mitsubishi Tanabe Pharma; other support from AstraZeneca; grants, personal fees, and other support from Bayer, Bristol Myers Squibb, Chugai, Daiichi Sankyo, MSD, and Ono Pharmaceutical; grants and personal fees from DaiNihonSumitomo, Eisai, Kyowa-Kirin, Sanofi, Takeda, Taiho, and Lilly; personal fees from Celgene, Ohtsuka, Genomic Health, AbbVie, and Amgen; and personal fees and other support from Pfizer outside the submitted work. S. Ferretti reports other support from Novartis outside the submitted work. C. Meille reports personal fees from Novartis during the conduct of the study, as well as personal fees from Novartis outside the submitted work. B. Pereira reports non-financial support from ArticulateScience during the conduct of the study, as well as other support from Novartis outside the submitted work; B. Pereira is a full-time employee of Novartis. L. Mariconti reports personal fees from Novartis during the conduct of the study, as well as personal fees from Novartis outside the submitted work. E. Halilovic reports to be an employee and a stockholder of Novartis. C. Fabre reports other support from Novartis during the conduct of the study, as well as other

support from Novartis outside the submitted work. No disclosures were reported by the other authors.

Authors' Contributions

E.M. Stein: Resources, investigation, writing–review and editing. **D.J. DeAngelo:** Resources, investigation, writing–review and editing. **J. Chromik:** Resources, investigation, writing–review and editing. **M. Chatterjee:** Resources, investigation, writing–review and editing. **S. Bauer:** Resources, investigation, writing–review and editing. **C.-C. Lin:** Resources, investigation, writing–review and editing. **C. Suarez:** Resources, investigation, writing–review and editing. **F. de Vos:** Resources, investigation, writing–review and editing. **N. Steeghs:** Resources, investigation, writing–review and editing. **P.A. Cassier:** Resources, investigation, writing–review and editing. **D. Tai:** Resources, investigation, writing–review and editing. **J.-J. Kiladjian:** Resources, investigation, writing–review and editing. **N. Yamamoto:** Resources, investigation, writing–review and editing. **R. Mous:** Resources, investigation, writing–review and editing. **J. Esteve:** Resources, investigation, writing–review and editing. **H. Minami:** Resources, investigation, writing–review and editing. **S. Ferretti:** Resources, formal analysis, investigation, methodology, writing–review and editing. **N. Guerreiro:** Conceptualization, resources, formal analysis, supervision, investigation, visualization, methodology, writing–original draft, writing–review and editing. **C. Meille:** Resources, formal analysis, investigation, visualization, methodology, writing–original draft, writing–review and editing. **R. Radhakrishnan:** Resources, formal analysis, validation, investigation, visualization, methodology, writing–original draft, writing–review and editing. **B. Pereira:** Resources, formal analysis, validation, investigation, visualization, writing–review and editing. **L. Mariconti:** Conceptualization, resources, data curation, investigation, writing–review and editing. **E. Halilovic:** Conceptualization, resources, formal analysis, supervision, investigation, visualization, writing–original draft, writing–review and editing. **C. Fabre:** Conceptualization, resources, supervision, investigation, writing–review and editing. **C. Carpio:** Resources, formal analysis, investigation, visualization, writing–review and editing.

Acknowledgments

The authors would like to thank the patients who participated in this study, along with their families. The authors also thank Matthieu Klopfenstein, Audrey Kaag, Astrid Jullion, Anil Gaur, Sebastian Szpakowski, Swann Gaulis, Arun Kumar, and Jens Wuerthner for their contributions to the study. Ram Reddy Kanthala is thanked for leading the programming activities for the study. This study was sponsored by Novartis Pharmaceuticals Corporation. Medical writing assistance was provided by Zoe Crossman, PhD, of ArticulateScience, and was funded by Novartis Pharmaceuticals Corporation.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 8, 2021; revised July 13, 2021; accepted November 29, 2021; published first December 2, 2021.

References

- Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. *Nature* 2000;408:307–10.
- Pant V, Lozano G. Limiting the power of p53 through the ubiquitin proteasome pathway. *Genes Dev* 2014;28:1739–51.
- Tsvetkov P, Reuven N, Shaul Y. Ubiquitin-independent p53 proteasomal degradation. *Cell Death Differ* 2010;17:103–8.
- Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. *Nature* 1997;387:299–303.
- Haupt Y, Maya R, Kazan A, Oren M. Mdm2 promotes the rapid degradation of p53. *Nature* 1997;387:296–9.
- Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. *Nature* 1993;362:857–60.
- Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. *FEBS Lett* 1997;420:25–7.
- Shadfan M, Lopez-Pajares V, Yuan ZM. MDM2 and MDMX: alone and together in regulation of p53. *Transl Cancer Res* 2012;1:88–9.
- Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. *Nat Rev Cancer* 2009;9:749–58.
- Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. *Nature* 2010;463:899–905.
- Zhao Y, Aguilar A, Bernard D, Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 inhibitors) in clinical trials for cancer treatment. *J Med Chem* 2015;58:1038–52.
- Jeay S, Gaulis S, Ferretti S, Bitter H, Ito M, Valat T, et al. A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097. *Elife* 2015;4:e06498.
- Konopleva M, Martinelli G, Daver N, Papayannidis C, Wei A, Higgins B, et al. MDM2 inhibition: an important step forward in cancer therapy. *Leukemia* 2020; 34:2858–74.
- Mascarenhas J, Lu M, Kosiorek H, Virtgym E, Xia L, Sandy L, et al. Oral idasanutlin in patients with polycythemia vera. *Blood* 2019;134:525–33.

15. Erba HP, Becker PS, Shami PJ, Grunwald MR, Flesher DL, Zhu M, et al. Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia. *Blood Adv* 2019;3:1939–49.
16. Bauer TM, Gounder MM, Weise AM, Schwartz GK, Carvajal RD, Kumar P, et al. A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L). *J Clin Oncol* 2018;36:11514.
17. Khurana A, Shafer DA. MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388). *Onco Targets Ther* 2019;12:2903–10.
18. Jeay S, Chene P, Ferretti S, Furet P, Gruenenfelder B, Guagnano V, et al. NVP-HDM201: cellular and in vivo profile of a novel highly potent and selective PPI inhibitor of p53-Mdm2. *Cancer Res* 2016;76:1225.
19. Ferretti S, Rebmann R, Berger M, Santacroce F, Albrecht G, Pollehn K, et al. Insights into the mechanism of action of NVP-HDM201, a differentiated and versatile next-generation small-molecule inhibitor of Mdm2, under evaluation in phase I clinical trials. *Cancer Res* 2016;76:1224.
20. Meille C, Guerreiro N, Jullion A, Bauer S, Chatterjee M, de Vos F, et al. Optimization of the dose and schedule of an HDM2 inhibitor NVP-HDM201 in a first-in-human Phase I study using a mechanism-based PK/PD model. *Cancer Res* 2017;77:CT154.
21. Jeay S, Ferretti S, Holzer P, Fuchs J, Chapeau EA, Wartmann M, et al. Dose and schedule determine distinct molecular mechanisms underlying the efficacy of the p53-MDM2 inhibitor HDM201. *Cancer Res* 2018;78:6257–67.
22. Neuenschwander B, Branson M, Gsponer T. Critical aspects of the Bayesian approach to phase I cancer trials. *Stat Med* 2008;27:2420–39.
23. Guerreiro N, Jullion A, Ferretti S, Fabre C, Meille C. Translational modeling of anticancer efficacy to predict clinical outcomes in a first-in-human phase 1 study of MDM2 inhibitor HDM201. *AAPS J* 2021;23:28.
24. Foundation Medicine I. 2017 30/06/2021. FoundationOne CDx technical information. [cited 2021 Jun 30]. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019C.pdf.
25. Friberg LE, Henningson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. *J Clin Oncol* 2002;20:4713–21.
26. Meille C, Guerreiro N, Fabre C, Jullion A. Dosing regimen selection supported by population PKPD model of thrombocytopenia. Montreux, Switzerland: PAGE; 2018.
27. Wang Z, Sun Y. Targeting p53 for novel anticancer therapy. *Transl Oncol* 2010;3:1–12.
28. Bykov VJN, Eriksson SE, Bianchi J, Wiman KG. Targeting mutant p53 for efficient cancer therapy. *Nat Rev Cancer* 2018;18:89–102.
29. Mahfoudhi E, Lordier L, Marty C, Pan J, Roy A, Roy L, et al. P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis. *Oncotarget* 2016;7:31980–92.
30. Tisato V, Voltan R, Gonelli A, Secchiero P, Zauli G. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer. *J Hematol Oncol* 2017;10:133.
31. Retout S, Meille C, Nichols G, Middleton S, Bottino D, Frey N. Prediction of occurrence of thrombocytopenia to select phase 1b dose and dosing regimen for a selective inhibitor of p53-MDM2 in patients with solid tumors. Venice, Italy: PAGE; 2012.
32. Sirvent N, Coindre JM, Maire G, Hostein I, Keslair F, Guillou L, et al. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. *Am J Surg Pathol* 2007;31:1476–89.
33. Weaver J, Goldblum JR, Turner S, Tubbs RR, Wang WL, Lazar AJ, et al. Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma. *Mod Pathol* 2009;22:66–70.
34. Fischer T, Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C, et al. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. *J Clin Oncol* 2010;28:4339–45.
35. Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. *Cancer Discov* 2016;6:1106–17.
36. Barbosa K, Li S, Adams PD, Deshpande AJ. The role of TP53 in acute myeloid leukemia: challenges and opportunities. *Genes Chromosomes Cancer* 2019;58:875–88.
37. Jung J, Lee JS, Dickson MA, Schwartz GK, Le Cesne A, Varga A, et al. TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in dedifferentiated liposarcoma. *Nat Commun* 2016;7:12609.